Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Dipyridamole 25mg
Boehringer Ingelheim (NZ) Limited
Dipyridamole 25 mg
25 mg
Tablet
Active: Dipyridamole 25mg Excipient: Magnesium stearate
Blister pack, 84 tablets, 84 tablets
Prescription
Prescription
Boehringer Ingelheim Espana SA
indicated as an adjunct to oral anticoagulation for the prophylaxis of thromboembolism associated with mechanical prosthetic heart valves.
Package - Contents - Shelf Life: Blister pack, - 84 tablets - 60 months from date of manufacture stored at or below 30°C
1969-12-31
NEW ZEALAND CONSUMER MEDICINE INFORMATION PERSANTIN ® 25 MG TABLETS _DIPYRIDAMOLE TABLETS _ This leaflet answers some common questions about PERSANTIN 25 mg tablets. It does not contain all available information. It does not take the place of talking to your doctor or pharmacist. Keep this information with your tablets. You may need to read it again later. _TO FIND OUT MORE ABOUT PERSANTIN 25 MG TABLETS _ You should ask your doctor or pharmacist if you have any questions about your medicine or if you have any concerns about taking PERSANTIN 25 mg tablets. WHAT PERSANTIN 25 MG TABLETS ARE USED FOR PERSANTIN 25 mg tablets are used in combination with other medicines helps to prevent blood clots in patients with prosthetic heart valves. The ability of PERSANTIN 25 mg tablets to prevent blood clots is due to its effect on blood cells known as platelets. If you want more information, ask your doctor or pharmacist. BEFORE TAKING PERSANTIN 25 MG TABLETS _WHEN NOT TO TAKE PERSANTIN 25 MG TABLETS _ Only take PERSANTIN 25 mg tablets if it has been prescribed for you by a doctor. Never give it to someone else even if their symptoms seem to be the same as yours. Do not take PERSANTIN 25 mg tablets if you are allergic to it or to any of the ingredients. These ingredients are listed in full at the end of this leaflet. If you are uncertain as to whether you have such an allergy you should raise this concern with your doctor. You should never take PERSANTIN 25 mg tablets after the EXPIRY DATE on the carton or b Read the complete document
NEW ZEALAND DATASHEET NAME OF MEDICINE PERSANTIN ® Dipyridamole PRESENTATION _Tablet 25 mg_ : Round, orange, shiny, biconvex sugar-coated tablet. _Perlonget_ ® _ (modified release capsule) 150 mg_ : Pink/white, opaque, hard gelatine capsule filled with yellow pellets. _Perlonget_ ® _ (modified release capsule) 200 mg_ : Red/orange, hard gelatine capsule filled with yellow pellets. USES ACTIONS Dipyridamole, the active ingredient of PERSANTIN, inhibits the uptake of adenosine into the erythrocytes, platelets and endothelial cells in vitro and in vivo; the inhibition amounts to 80% at its maximum and occurs dose-dependently at therapeutic concentrations (0.5 - 2 mcg/ml). Consequently, there is an increased concentration of adenosine locally at the platelet A2-receptor, stimulating platelet adenylate cyclase, thereby increasing platelet cAMP levels. Thus, platelet aggregation in response to various stimuli such as PAF, collagen and ADP is inhibited. Reduced platelet aggregation reduces platelet consumption towards normal levels. In addition, adenosine has a vasodilator effect and this is one of the mechanisms by which dipyridamole produces vasodilation. Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. Whilst the inhibition of cAMP- PDE is weak, therapeutic levels inhibit cGMP-PDE, thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, identified as NO). Dipyridamole also stimulates the biosynthesis and release of prostacyclin by the endothelium. Dipyridamole reduces the thrombogenicity of subendothelial structures by in Read the complete document